• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

Comprehensive Guide to (R)-2-((tert-Butoxycarbonyl)amino)-2,4-dimethylpentanoic acid (CAS No. 1393524-04-3)

(R)-2-((tert-Butoxycarbonyl)amino)-2,4-dimethylpentanoic acid (CAS No. 1393524-04-3) is a specialized chiral compound widely used in pharmaceutical research, peptide synthesis, and organic chemistry. This Boc-protected amino acid derivative is valued for its role in asymmetric synthesis and drug development. Its unique structure, featuring a tert-butoxycarbonyl (Boc) protecting group and a branched alkyl chain, makes it a versatile building block for complex molecules.

The compound's chiral center at the 2-position ensures high stereoselectivity, a critical factor in modern drug design. Researchers frequently employ (R)-2-((tert-Butoxycarbonyl)amino)-2,4-dimethylpentanoic acid in the synthesis of peptidomimetics and bioactive compounds targeting neurological disorders and metabolic diseases. Recent interest in personalized medicine and targeted drug delivery has further amplified demand for such chiral intermediates.

From a chemical perspective, this compound exhibits excellent stability under standard conditions, with solubility in common organic solvents like dichloromethane (DCM), tetrahydrofuran (THF), and dimethylformamide (DMF). The Boc-protecting group can be selectively removed under mild acidic conditions, making it ideal for multi-step syntheses. These properties align with current industry trends toward green chemistry and atom-efficient processes.

In pharmaceutical applications, CAS 1393524-04-3 serves as a key intermediate for protease inhibitors and G-protein-coupled receptor (GPCR) modulators. The compound's 2,4-dimethylpentanoic acid backbone contributes to enhanced lipophilicity, improving membrane permeability—a sought-after characteristic in CNS drug development. This correlates with growing research into blood-brain barrier penetration technologies.

The market for chiral building blocks like (R)-2-((tert-Butoxycarbonyl)amino)-2,4-dimethylpentanoic acid continues to expand, driven by the biopharmaceutical boom and increased R&D investment in orphan drugs. Analytical techniques such as HPLC and chiral chromatography are essential for quality control, ensuring enantiomeric purity >99% for critical applications. These methodologies address the pharmaceutical industry's emphasis on quality by design (QbD) principles.

Recent innovations in continuous flow chemistry have enabled more efficient production of such compounds, reducing waste and improving yield. The tert-butoxycarbonyl group in this molecule facilitates cleaner deprotection compared to alternative protecting groups, aligning with process intensification strategies. These advancements respond to the chemical industry's focus on sustainable manufacturing practices.

For researchers exploring structure-activity relationships (SAR), this compound offers valuable opportunities to study steric effects and conformational constraints. The 2,4-dimethyl substitution pattern provides insights into van der Waals interactions and hydrophobic binding—key considerations in rational drug design. Such investigations support the growing field of computational chemistry and molecular modeling.

Storage and handling recommendations for CAS 1393524-04-3 include protection from moisture at recommended temperatures (-20°C). Proper storage maintains the integrity of both the carboxylic acid functionality and the Boc-protected amine. These protocols reflect current best practices in chemical inventory management for research facilities.

The compound's applications extend beyond pharmaceuticals into material science, where it serves as a monomer for specialty polymers. Its branched structure influences polymer chain packing and thermal properties—an area of interest for advanced material development. This versatility makes it valuable in emerging fields like biodegradable plastics research.

Analytical characterization of (R)-2-((tert-Butoxycarbonyl)amino)-2,4-dimethylpentanoic acid typically involves NMR spectroscopy (1H, 13C), mass spectrometry, and optical rotation measurements. These techniques verify both chemical structure and enantiomeric purity, meeting the stringent requirements of regulatory submissions in drug development pipelines.

With the increasing importance of chiral purity in regulatory approvals, compounds like 1393524-04-3 play a pivotal role in modern medicinal chemistry. The pharmaceutical industry's shift toward enantiomerically pure drugs has created sustained demand for such building blocks, particularly in small molecule therapeutics development for oncology and immunology applications.

Future research directions may explore novel derivatives of this compound for bioconjugation applications or as components of drug-linker systems in antibody-drug conjugates (ADCs). The compound's structural features make it suitable for click chemistry modifications, aligning with trends in modular synthesis approaches. Such developments could further expand its utility in biopharmaceutical innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)